The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer-Reference-Cited by-同舟云学术

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Published:2016-10 Issue:4 Volume:70 Page:675-683
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Evans Christopher P.,Higano Celestia S.,Keane Thomas,Andriole Gerald,Saad Fred,Iversen Peter,Miller Kurt,Kim Choung-Soo,Kimura Go,Armstrong Andrew J.,Sternberg Cora N.,Loriot Yohann,de Bono Johann,Noonberg Sarah B.,Mansbach Hank,Bhattacharya Suman,Perabo Frank,Beer Tomasz M.,Tombal Bertrand

Publisher

Elsevier BV

Subject

Urology

Reference17 articles.

1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. GLOBOCAN Web site. http://globocan.iarc.fr.

2. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Web site. http://seer.cancer.gov.

3. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006;Sathiakumar;Prostate Cancer Prostatic Dis,2011

4. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases;Zustovich;Crit Rev Oncol Hematol,2014

5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A noncanonical E3 ubiquitin ligase RNF41-mediated MYO1C stability promotes prostate cancer metastasis by inducing actin remodeling;Oncogene;2024-08-07

2. Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient;Journal of Oncology Pharmacy Practice;2024-07-23

3. Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer;BMJ Open;2024-07

4. Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments;Journal of Geriatric Oncology;2024-04

5. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial;European Urology Oncology;2024-04